Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus PSORCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus PSORCON.
DERMA-SMOOTHE/FS vs PSORCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid